• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".

作者信息

Barreto Andrew D, Grotta James C

机构信息

Department of Neurology, Stroke Program, McGovern Medical School at The University of Texas Health Science Center (UTHSC) at Houston.

Clinical Innovation and Research Institute, Memorial Hermann Hospital -Texas Medical Center, Houston.

出版信息

Stroke. 2017 Sep;48(9):e259. doi: 10.1161/STROKEAHA.117.018294. Epub 2017 Jul 28.

DOI:10.1161/STROKEAHA.117.018294
PMID:28754829
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5608620/
Abstract
摘要

相似文献

1
Response by Barreto and Grotta to Letter Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".巴雷托和格罗塔对关于文章《ARTSS - 2（阿加曲班联合重组组织型纤溶酶原激活剂治疗急性卒中的随机、多中心试验）》的信件的回应
Stroke. 2017 Sep;48(9):e259. doi: 10.1161/STROKEAHA.117.018294. Epub 2017 Jul 28.
2
Letter by Shah Regarding Article, "Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke)".沙阿就“ARTSS - 2（阿加曲班联合重组组织型纤溶酶原激活剂治疗急性卒中的随机、多中心试验）”一文所写的信。
Stroke. 2017 Sep;48(9):e258. doi: 10.1161/STROKEAHA.117.018121. Epub 2017 Jul 28.
3
Recombinant tissue-type plasminogen activator plus eptifibatide versus recombinant tissue-type plasminogen activator alone in acute ischemic stroke: propensity score-matched post hoc analysis.重组组织型纤溶酶原激活剂联合依替巴肽与单用重组组织型纤溶酶原激活剂治疗急性缺血性卒中的倾向评分匹配事后分析
Stroke. 2015 Feb;46(2):461-4. doi: 10.1161/STROKEAHA.114.006743. Epub 2014 Dec 18.
4
Should we exclude acute stroke patients with previous intracerebral hemorrhage from receiving intravenous thrombolysis?急性脑梗死患者既往有颅内出血者是否应排除静脉溶栓治疗？
Int J Stroke. 2016 Oct;11(7):783-90. doi: 10.1177/1747493016654289. Epub 2016 Jun 16.
5
Thirty Years After the National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Trial: A New Era for Stroke Therapy.
JAMA Neurol. 2016 Mar;73(3):265-7. doi: 10.1001/jamaneurol.2015.4453.
6
Response by Sposato et al to Letter Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".斯波萨托等人对关于文章《右岛叶受累对IST - 3试验（第三次国际中风试验）中急性缺血性中风后死亡和功能结局的影响》的信件的回应
Stroke. 2017 Mar;48(3):e92. doi: 10.1161/STROKEAHA.116.016387. Epub 2017 Feb 7.
7
Drip-and-Ship Thrombolytic Therapy for Acute Ischemic Stroke.急性缺血性卒中的静脉滴注联合血管内取栓溶栓治疗
J Stroke Cerebrovasc Dis. 2018 Jan;27(1):61-67. doi: 10.1016/j.jstrokecerebrovasdis.2017.07.033. Epub 2017 Sep 1.
8
Combined lysis of thrombus with ultrasound and systemic tissue plasminogen activator for emergent revascularization in acute ischemic stroke (CLOTBUST-ER): design and methodology of a multinational phase 3 trial.超声联合全身组织纤溶酶原激活剂溶解血栓用于急性缺血性卒中紧急血管再通（CLOTBUST-ER）：一项跨国3期试验的设计与方法
Int J Stroke. 2015 Oct;10(7):1141-8. doi: 10.1111/ijs.12536. Epub 2015 Jun 29.
9
Letter by Alves et al Regarding Article, "Effect of Right Insular Involvement on Death and Functional Outcome After Acute Ischemic Stroke in the IST-3 Trial (Third International Stroke Trial)".阿尔维斯等人就文章《右岛叶受累对IST - 3试验（第三次国际中风试验）中急性缺血性中风后死亡及功能转归的影响》所写的信
Stroke. 2017 Mar;48(3):e91. doi: 10.1161/STROKEAHA.116.016373. Epub 2017 Feb 7.
10
Solitaire™ with the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke (SWIFT PRIME) trial: protocol for a randomized, controlled, multicenter study comparing the Solitaire revascularization device with IV tPA with IV tPA alone in acute ischemic stroke.以血栓切除术为主要血管内治疗手段治疗急性缺血性卒中的Solitaire™（SWIFT PRIME）试验：一项随机对照多中心研究方案，比较Solitaire血管再通装置联合静脉注射组织型纤溶酶原激活剂（IV tPA）与单纯静脉注射IV tPA治疗急性缺血性卒中的疗效。
Int J Stroke. 2015 Apr;10(3):439-48. doi: 10.1111/ijs.12459.

本文引用的文献

1
Randomized, Multicenter Trial of ARTSS-2 (Argatroban With Recombinant Tissue Plasminogen Activator for Acute Stroke).ARTSS-2（阿加曲班联合重组组织型纤溶酶原激活剂治疗急性卒中）的随机多中心试验
Stroke. 2017 Jun;48(6):1608-1616. doi: 10.1161/STROKEAHA.117.016720. Epub 2017 May 15.
2
Argatroban tPA stroke study: study design and results in the first treated cohort.阿加曲班与组织型纤溶酶原激活剂治疗卒中研究：首个治疗队列的研究设计与结果
Arch Neurol. 2006 Aug;63(8):1057-62. doi: 10.1001/archneur.63.8.1057.
3
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke.在栓塞性中风大鼠模型中，阿加曲班对重组组织型纤溶酶原激活剂治疗窗的扩展作用。
Stroke. 2001 Nov;32(11):2635-40. doi: 10.1161/hs1101.097390.
4
A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study.
J Am Coll Cardiol. 1999 Jun;33(7):1879-85. doi: 10.1016/s0735-1097(99)00107-2.